| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
FINANCIAL SUMMARY
Immutep continued to prudently manage its cashflow over the first quarter of the new financial year (Q1 FY24), while strategically investing into clinical trial programs for efti.
With a cash and cash equivalent balance as at 30 September 2023 of approximately $110.1 million, Immutep's cash position remains very strong with an expected cash reach till early CY2026.
The Company has sufficient capital to reach key milestones that will potentially add value to efti and IMP761.
Cash receipts from customers in Q1 FY24 were $132k, compared to $16k in Q4 FY23. The net cash used in G&A activities in the quarter was $1.61 million, which is the same as Q4 FY23.
Payments of $464k to Related Parties, for the quarter, comprises Non-Executive Directors' fees and Executive Directors' remuneration.
The net cash used in R&D activities in the quarter was $9.72 million, compared to $5.41 million in Q4 FY23. The increase in cash used for the quarter was mainly due to increased clinical trial activities.
Total net cash outflows used in operating activities in the quarter was $12.86 million compared to $8.35 million in Q4 FY23.
Payment for the acquisition of Intellectual Property was $328k in Q1 FY24, compared to nil in Q4 FY23.
Posted In: IMMP
